Published in:
01-09-2004 | Poster presentation
Zoledronic acid protects from local and systemic bone loss in tumor necrosis factor-mediated arthritis
Authors:
K Redlich, P Herrak, B Görtz, S Hayer, E Reiter, J Gasser, H Bergmeister, G Kollias, JS Smolen, G Schett
Published in:
Arthritis Research & Therapy
|
Special Issue 3/2004
Login to get access
Excerpt
Increased osteoclast activity is a key factor for bone loss in rheumatoid arthritis (RA). This suggests that osteoclast-targeted therapies could effectively prevent skeletal damage in RA. Zoledronic acid (ZA) is one of the most potent agents to block osteoclast function. We therefore investigated whether ZA can inhibit inflammatory bone loss. …